Mechanistically, treatment with CHIR99021 leads to an increased production of proinflammatory cytokines (IFN-γ, tumor necrosis factor α (TNFα)) and upregulates NK cytotoxicity against ovarian cancer cells [181]. This evidence concerns the gene TNF and ovarian carcinoma.